+データを開く
-基本情報
登録情報 | データベース: PDB / ID: 7m42 | ||||||
---|---|---|---|---|---|---|---|
タイトル | Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989 | ||||||
要素 |
| ||||||
キーワード | VIRAL PROTEIN/IMMUNE SYSTEM / SARS-Cov-2 / RBD / neutralizing antibody / VIRAL PROTEIN-IMMUNE SYSTEM complex | ||||||
機能・相同性 | 機能・相同性情報 Maturation of spike protein / viral translation / Translation of Structural Proteins / Virion Assembly and Release / host cell surface / host extracellular space / suppression by virus of host tetherin activity / Induction of Cell-Cell Fusion / structural constituent of virion / host cell endoplasmic reticulum-Golgi intermediate compartment membrane ...Maturation of spike protein / viral translation / Translation of Structural Proteins / Virion Assembly and Release / host cell surface / host extracellular space / suppression by virus of host tetherin activity / Induction of Cell-Cell Fusion / structural constituent of virion / host cell endoplasmic reticulum-Golgi intermediate compartment membrane / entry receptor-mediated virion attachment to host cell / receptor-mediated endocytosis of virus by host cell / Attachment and Entry / membrane fusion / positive regulation of viral entry into host cell / receptor-mediated virion attachment to host cell / receptor ligand activity / host cell surface receptor binding / fusion of virus membrane with host plasma membrane / fusion of virus membrane with host endosome membrane / viral envelope / virion attachment to host cell / SARS-CoV-2 activates/modulates innate and adaptive immune responses / host cell plasma membrane / virion membrane / identical protein binding / membrane / plasma membrane 類似検索 - 分子機能 | ||||||
生物種 | Homo sapiens (ヒト) Severe acute respiratory syndrome coronavirus 2 (ウイルス) | ||||||
手法 | 電子顕微鏡法 / 単粒子再構成法 / クライオ電子顕微鏡法 / 解像度: 3.3 Å | ||||||
データ登録者 | Zhou, Y. / Romero Hernandez, A. / Saotome, K. / Franklin, M.C. | ||||||
引用 | ジャーナル: Cell / 年: 2021 タイトル: The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. 著者: Richard Copin / Alina Baum / Elzbieta Wloga / Kristen E Pascal / Stephanie Giordano / Benjamin O Fulton / Anbo Zhou / Nicole Negron / Kathryn Lanza / Newton Chan / Angel Coppola / Joyce Chiu ...著者: Richard Copin / Alina Baum / Elzbieta Wloga / Kristen E Pascal / Stephanie Giordano / Benjamin O Fulton / Anbo Zhou / Nicole Negron / Kathryn Lanza / Newton Chan / Angel Coppola / Joyce Chiu / Min Ni / Yi Wei / Gurinder S Atwal / Annabel Romero Hernandez / Kei Saotome / Yi Zhou / Matthew C Franklin / Andrea T Hooper / Shane McCarthy / Sara Hamon / Jennifer D Hamilton / Hilary M Staples / Kendra Alfson / Ricardo Carrion / Shazia Ali / Thomas Norton / Selin Somersan-Karakaya / Sumathi Sivapalasingam / Gary A Herman / David M Weinreich / Leah Lipsich / Neil Stahl / Andrew J Murphy / George D Yancopoulos / Christos A Kyratsous / 要旨: Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight ...Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment-induced emergent resistance. To this end, we investigated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well as in preclinical in vitro studies using single, dual, or triple antibody combinations, and in hamster in vivo studies using REGEN-COV or single monoclonal antibody treatments. Our study demonstrates that the combination of non-competing antibodies in REGEN-COV provides protection against all current SARS-CoV-2 variants of concern/interest and also protects against emergence of new variants and their potential seeding into the population in a clinical setting. | ||||||
履歴 |
|
-構造の表示
ムービー |
ムービービューア |
---|---|
構造ビューア | 分子: MolmilJmol/JSmol |
-ダウンロードとリンク
-ダウンロード
PDBx/mmCIF形式 | 7m42.cif.gz | 231 KB | 表示 | PDBx/mmCIF形式 |
---|---|---|---|---|
PDB形式 | pdb7m42.ent.gz | 160.8 KB | 表示 | PDB形式 |
PDBx/mmJSON形式 | 7m42.json.gz | ツリー表示 | PDBx/mmJSON形式 | |
その他 | その他のダウンロード |
-検証レポート
文書・要旨 | 7m42_validation.pdf.gz | 821.5 KB | 表示 | wwPDB検証レポート |
---|---|---|---|---|
文書・詳細版 | 7m42_full_validation.pdf.gz | 829.9 KB | 表示 | |
XML形式データ | 7m42_validation.xml.gz | 34.4 KB | 表示 | |
CIF形式データ | 7m42_validation.cif.gz | 51.3 KB | 表示 | |
アーカイブディレクトリ | https://data.pdbj.org/pub/pdb/validation_reports/m4/7m42 ftp://data.pdbj.org/pub/pdb/validation_reports/m4/7m42 | HTTPS FTP |
-関連構造データ
-リンク
-集合体
登録構造単位 |
|
---|---|
1 |
|
-要素
-抗体 , 4種, 4分子 ABCD
#1: 抗体 | 分子量: 22709.975 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) 発現宿主: Cricetulus griseus (モンゴルキヌゲネズミ) |
---|---|
#2: 抗体 | 分子量: 24815.834 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) 発現宿主: Cricetulus griseus (モンゴルキヌゲネズミ) |
#4: 抗体 | 分子量: 22895.180 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) 発現宿主: Cricetulus griseus (モンゴルキヌゲネズミ) |
#5: 抗体 | 分子量: 24857.811 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) 発現宿主: Cricetulus griseus (モンゴルキヌゲネズミ) |
-タンパク質 / 糖 , 2種, 2分子 E
#3: タンパク質 | 分子量: 28437.902 Da / 分子数: 1 / Fragment: receptor binding domain (UNP residues 319-541) / 由来タイプ: 組換発現 由来: (組換発現) Severe acute respiratory syndrome coronavirus 2 (ウイルス) 遺伝子: S, 2 発現宿主: Cricetulus griseus (モンゴルキヌゲネズミ) 参照: UniProt: P0DTC2 |
---|---|
#6: 多糖 | beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta- ...beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose |
-詳細
研究の焦点であるリガンドがあるか | N |
---|
-実験情報
-実験
実験 | 手法: 電子顕微鏡法 |
---|---|
EM実験 | 試料の集合状態: PARTICLE / 3次元再構成法: 単粒子再構成法 |
-試料調製
構成要素 | 名称: Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989 タイプ: COMPLEX / Entity ID: #1-#5 / 由来: MULTIPLE SOURCES |
---|---|
由来(天然) | 生物種: Severe acute respiratory syndrome coronavirus 2 (ウイルス) |
由来(組換発現) | 生物種: Cricetulus griseus (モンゴルキヌゲネズミ) |
緩衝液 | pH: 7.5 |
試料 | 包埋: NO / シャドウイング: NO / 染色: NO / 凍結: YES |
急速凍結 | 凍結剤: ETHANE |
-電子顕微鏡撮影
実験機器 | モデル: Titan Krios / 画像提供: FEI Company |
---|---|
顕微鏡 | モデル: FEI TITAN KRIOS |
電子銃 | 電子線源: FIELD EMISSION GUN / 加速電圧: 300 kV / 照射モード: FLOOD BEAM |
電子レンズ | モード: BRIGHT FIELD |
撮影 | 電子線照射量: 40 e/Å2 フィルム・検出器のモデル: GATAN K3 BIOQUANTUM (6k x 4k) |
-解析
ソフトウェア |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTF補正 | タイプ: PHASE FLIPPING AND AMPLITUDE CORRECTION | ||||||||||||||||||||||||
3次元再構成 | 解像度: 3.3 Å / 解像度の算出法: FSC 0.143 CUT-OFF / 粒子像の数: 146054 / 対称性のタイプ: POINT | ||||||||||||||||||||||||
精密化 | 交差検証法: NONE 立体化学のターゲット値: GeoStd + Monomer Library + CDL v1.2 | ||||||||||||||||||||||||
原子変位パラメータ | Biso mean: 56.34 Å2 | ||||||||||||||||||||||||
拘束条件 |
|